Kumana Cyrus R, Mak Raymond, Kwong Yok-Lam, Gill Harinder
Department of Medicine, The University of Hong Kong, Hong Kong, China.
Department of Pharmacy, Queen Mary Hospital, Hong Kong, China.
Front Oncol. 2020 Aug 4;10:1294. doi: 10.3389/fonc.2020.01294. eCollection 2020.
Various forms of arsenic were used in China and elsewhere for over 5,000 years. Following the initial success of intravenous arsenic trioxide (i.v. AsO), we revived an oral formulation of pure AsO in 1998 for the treatment of acute promyelocytic leukemia (APL). We were the first to produce a 1 mg/ml oral-AsO solution and showed that it had comparable bioavailability to i.v. AsO. Moreover, we also reported that intracellular arsenic concentrations were considerably higher than the corresponding plasma values. Our oral-AsO was patented internationally and registered in Hong Kong for the treatment of APL. Safety, tolerability and clinical efficacy was confirmed in long-term follow-up studies. We have extended the use of oral-AsO to frontline induction of newly diagnosed APL. With these findings, we are moving toward an era of completely oral and chemotherapy-free management of APL.
在中国及其他地区，各种形式的砷已被使用了5000多年。继静脉注射三氧化二砷（i.v. AsO）取得初步成功后，我们于1998年恢复了纯AsO口服制剂用于治疗急性早幼粒细胞白血病（APL）。我们率先生产出1mg/ml的口服AsO溶液，并表明其生物利用度与静脉注射AsO相当。此外，我们还报告称细胞内砷浓度明显高于相应的血浆值。我们的口服AsO获得了国际专利，并在香港注册用于治疗APL。长期随访研究证实了其安全性、耐受性和临床疗效。我们已将口服AsO的应用扩展到新诊断APL的一线诱导治疗。基于这些发现，我们正迈向一个完全口服且无需化疗的APL管理时代。
